
# ASSESSING PATIENT-REPORTED OUTCOMES AND SPECIALTY PHARMACIST INTERVENTIONS IN MULTIPLE SCLEROSIS





E. Danielle Bryan, PharmD<sup>1</sup> | Rebekah Finley, PharmD candidate<sup>2</sup> | Nisha B. Shah, PharmD<sup>1</sup> | Ryan Moore, MS<sup>3</sup> | Megan Peter, PhD<sup>1</sup> | Leena Choi, PhD<sup>3</sup> | Autumn D. Zuckerman, PharmD, BCPS, AAHIVP, CSP<sup>1</sup> |

1 Vanderbilt Specialty Pharmacy, Vanderbilt University Medical Center | <sup>2</sup>Lipscomb University College of Pharmacy | <sup>3</sup>Department of Biostatistics, Vanderbilt University Medical Center

### **BACKGROUND**

- Patient reported outcomes (PROs) are used to assess response to medication and the need for therapeutic adjustments in patients with multiple sclerosis (MS).<sup>1,2</sup>
- Vanderbilt Specialty Pharmacy assesses PROs through monthly refill questionnaires (MRQs) to help guide specialty pharmacist interventions.

# **OBJECTIVE**

To assess PROs and pharmacist interventions in patients prescribed specialty multiple sclerosis (MS) medications at a health-system specialty pharmacy.

### **METHODS**

DESIGN	Single-center retrospective analysis	
INCLUSION	Patients prescribed a MS specialty medication by center's outpatient MS clinic provider with:	

- 2+ fills through the center's specialty pharmacy, AND
- 2+ MRQs from January to March 2020

## **OUTCOMES**

- Adverse effects (AE)
- Missed doses and reasons
- Perceived effectiveness
- Specialty pharmacist interventions


	TABLE 1. DEMOGRAPHICS (n=335)		
		n (%) or	
		median (IQR)	
	Age, years	45 (52-60)	
	Gender, female	256 (76)	
	Race		
	White	274 (82)	
	Black	50 (15)	
	Unknown	9 (3)	
	Other	2 (<1)	
	Insurance type		
	Commercial	196 (59)	
	Medicare	127 (38)	
	Medicaid	12 (4)	
	Diagnosis		
	Relapsing-remitting	295 (88)	
	Secondary progressive	27 (8)	
	Primary progressive	11 (3)	
	Clinically isolated syndrome	1 (<1)	
	Tumefactive	1 (<1)	
	Specialty medication		
	Fingolimod	74 (22)	
	Dimethyl fumarate	63 (19)	
)	Glatiramer acetate	56 (17)	
	Interferon beta-1a	56 (17)	
	Dalfampridine	33 (10)	
	Teriflunomide	32 (10)	
	Interferon beta-1b	13 (4)	
	Peginterferon beta-1a	7 (2)	
	Siponimod	1 (<1)	

## FIGURE 1. MONTHLY REFILL QUESTIONNAIRE AND WORKFLOW

Certified
Pharmacy
Technicians
perform an
assessment at
each monthly
medication refill
that includes the
following
questions that
may trigger
pharmacist
interventions.

Are you experiencing side effects?	Yes	Pharmacist performs intervention
	No	
Have you missed any doses of medication?	Yes	Pharmacist performs intervention
	No	
How well do you	Poor	Pharmacist performs intervention
think your medication is working for you?	Fair	
io ironang ior your	Good	
	Excellent	

# RESULTS



# FIGURE 3. MISSED DOSES

90% (n=301)

of patients
reported no
missed medication
doses

10% (n=34)
reported 1 or more
missed doses


Forgetfulness was the most reported explanation for missing 1 or more doses (n=22)

## FIGURE 4. PERCEIVED MEDICATION EFFECTIVENESS



98% (n=999) of MRQ responses reported medication effectiveness as 'good' or 'excellent'

### FIGURE 5. SPECIALTY PHARMACIST INTERVENTIONS (n=175)



Most common interventions were related to medication adherence, therapeutic monitoring/safety and side effects.

Interventions related to adherence most often included chart review or update and patient counseling.

Interventions related to therapeutic monitoring/safety typically included reviewing lab or therapy monitoring and making treatment recommendations.

### CONCLUSIONS

- Patients receiving medication through an integrated health-system specialty pharmacy reported low rates of missed doses (10%) and adverse effects (2%), and most rated high perceived effectiveness of their medication (95%).
- MS integrated specialty pharmacists perform targeted interventions to ensure safe and effective medication use.
- PROs can be used to direct patient's future course of therapy with the assistance of specialty pharmacist interventions.